“Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight
Nanomedicine for Cancer Therapies
Cancer Nanoparticles Drug Delivery Systems Classification
Mechanism of Cancer Nanomedicine Therapy
Cancer Nanomedicine Clinical Pipeline Overview
Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Cancer Nanomedicine Clinical Pipeline: 79 Drugs
Marketed Cancer Nanomedicine: 8 Drugs
An innovative clinical trail study design _First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.
Imaging allows a non-invasive assessment of biochemical and biological processes in a living subject. Monitoring, assessing, and characterising novel therapeutics in pre-clinical models is an essential part of drug development.
In this webinar Dr Juliana Maynard, Lead Scientist in Pre-clinical Imaging, and Dr Philippa Hart, Lead Scientist in Mass Spectrometry Imaging, explore available imaging technologies and techniques and explain how they can help at different stages of the drug development process.
di Pier Giuseppe Pelicci, MD-PhD, Istituto Europeo di Oncologia IEO, Università degli Studi di Milano.
Slide per l'intervento tenuto in Fondazione Giannino Bassetti in occasione del primo incontro del ciclo "La medicina di precisione", primo progetto dalla convenzione tra Università di Pavia e Fondazione Bassetti.
12 marzo 2018
FDA NGS and Big Data Conference September 2014Warren Kibbe
Presentation for the FDA NGS and Big Data Conference September 2014 held on the NIH campus. NCI initiatives, including Cancer Genomics Data Commons, NCI Cloud Pilots, big data issues for cancer
An innovative clinical trail study design _First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.
Imaging allows a non-invasive assessment of biochemical and biological processes in a living subject. Monitoring, assessing, and characterising novel therapeutics in pre-clinical models is an essential part of drug development.
In this webinar Dr Juliana Maynard, Lead Scientist in Pre-clinical Imaging, and Dr Philippa Hart, Lead Scientist in Mass Spectrometry Imaging, explore available imaging technologies and techniques and explain how they can help at different stages of the drug development process.
di Pier Giuseppe Pelicci, MD-PhD, Istituto Europeo di Oncologia IEO, Università degli Studi di Milano.
Slide per l'intervento tenuto in Fondazione Giannino Bassetti in occasione del primo incontro del ciclo "La medicina di precisione", primo progetto dalla convenzione tra Università di Pavia e Fondazione Bassetti.
12 marzo 2018
FDA NGS and Big Data Conference September 2014Warren Kibbe
Presentation for the FDA NGS and Big Data Conference September 2014 held on the NIH campus. NCI initiatives, including Cancer Genomics Data Commons, NCI Cloud Pilots, big data issues for cancer
UTSpeaks: A medicated nation
Has Australia lost its way in a pharmaceutical love affair?
Professor Charlie Benrimoj and Associate Professor Mary Bebawy from the University of Technology, Sydney present at this public lecture on prescription medication held on 13 September, 2011.
How many pills will you take today? Do you really need them? What good (and bad) will they do you?
For many of us prescription medications mean the difference between good and ill-health. There’s no denying their important place in fostering well-being for many. But is it time to reflect on the complex forces at work when managing disease and medications and how this impacts you the consumer?
Featuring leading UTS researchers in pharmacy and using example case studies, this public lecture takes a critical look at how medications are prescribed and consumed in Australia. It considers whether we are getting value for money, the ideal health outcomes we hope for and whether new approaches to the responsible use and explanation of medications could be adopted.
Speakers:
Professor Shalom (Charlie) Benrimoj
Charlie Benrimoj is head of the newly-created UTS School of Pharmacy. Formerly he was Foundation Professor of Pharmacy Practice then Dean of the Faculty of Pharmacy and then Pro-Vice Chancellor (Strategic Planning) at the University of Sydney. He is a visiting professor at the University of Granada with research interests in the future of community pharmacy. He is widely published - co-authoring Community Pharmacy: Strategic Change Management in 2007. He was Australian Pharmacist of the Year in 2000 and received the Andre Bedat award in 2010 from the International Pharmacy Federation.
Associate Professor Mary Bebawy
Mary Bebawy has spent more than 14 years in research and teaching positions in academia and two years in industry as a post doctoral preclinical drug development scientist with Johnson and Johnson, Research. She has consulted to academia and industry on assay development, drug discovery and cancer resistance mechanisms. At the UTS School of Pharmacy she specialises in the role and regulation of the xenobiotic cascade in drug disposition and in cancer multidrug resistance (MDR).
UTSPEAKS: is a free public lecture series presented by UTS experts discussing a range of important issues confronting contemporary Australia.
Use the hashtag #utspeaks to tweet about the lecture on Twitter.
OncoPrime - Patient derived platform for Biologics research Rachna Goyal
“OncoPrime™ platform uses patient-derived primary samples that offer clinically-relevant genotypic and
phenotypic diversity that translates better to the clinic vis-à-vis cell lines.
Functional assays, when adapted to OncoPrime™ can not only help in claiming physiological relevance
but also add additional layers of information for more informed clinical trials.
A Novel Eclectic Approach for Cancer Therapy with Liquid Knife & Immuno Thera...CrimsonpublishersCancer
Recent years cancer immunological therapy is getting very popular and many new drug have been approved by FDA like PD1 and PDl-1, however, in clinical practice of cancer treatment, it looks very limited efficacy for advanced cancer, so that physician started to use comprehensive plan by combination chemotherapy with PD1 as a novel strategy with a better clinical benefit. Since chemotherapy and radiation therapy always produce the side effect like loss hair, vomit and neutropenia, and surgery is limited for many later stages of cancers, also surgery damages body shapes with functions, esophageal cancer was removed with reconstruction and put stomach into chest and stomach never has normal function; a lot of cases showed surgery can’t be performed because tumor location in special site, like tumor location in posterior vaginal wall or vaginal carnal, surgery just is not allowed to do the procedure, if remove the tumor in these location, it will make a hole to connect to the rectal. Because of the extremely toxic side effects, many cancer patients cannot be successfully completed a surgery or a complete course of chemotherapy or radiation therapy, and some cases even die from the side effects of surgery or chemotherapy or radiation therapy due to a patient’s poor tolerance.
Non-animal models of NSCLC, Dr Dania MoviaKen Rogan
Dania Movia – PhD, MSc Senior Research Fellow Department of Clinical Medicine / Trinity Translational Medicine Institute Trinity College Dublin Predicting the efficacy of inhaled anti-cancer drugs in NSCLC patients
Cancer Moonshot, Data sharing and the Genomic Data CommonsWarren Kibbe
Gave the inaugural Informatics Grand Rounds at City of Hope on September 8th. NIH Commons, Genomic Data Commons, NCI Cloud Pilots, Cancer Moonshot and rationale for changing incentives around data sharing all discussed.
ZOOM: Pancreatic Cancer
• NEWS: Publication by Juan IOVANNA
• IMODI around the world: Meet the experts!
• FOCUS: From the bench to the bedside, INSERM U1068
• WEB-CATALOGUE: 20 in-vitro cell models available
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Cancer care is increasingly tailored to individual patients, who can undergo genetic or biomarker testing soon after diagnosis, to determine which treatments have the best chance of shrinking or eliminating tumours.
In this webinar, a pathologist and clinical oncologist discuss:
● how they are using these new tests,
● how they communicate results and treatment options to patients and caregivers, and
● how patients can be better informed on the kinds of tests that are in development or in use across Canada
View the video: https://youtu.be/_Wai_uMQKEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
Proteomics Modules designed to bring clinically relevant data, at any point, into the Drug Discovery Process. 1000s of proteins are plated from primary cells and are used to trap autoantibodies from diseased patients' blood sera. Results put a spotlight on highest probability targets.
“Europe Biosimilars Market & Pipeline Insight” Report Highlight:
Biosimilars Market Overview & Trend Analysis by Country
Biosimilars Introduction Timeline in Europe
Biosimilars Development & Market Authorization Guidelines
Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
Europe Biosimilars Pipeline: 93 Biosimilars
Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine)
UTSpeaks: A medicated nation
Has Australia lost its way in a pharmaceutical love affair?
Professor Charlie Benrimoj and Associate Professor Mary Bebawy from the University of Technology, Sydney present at this public lecture on prescription medication held on 13 September, 2011.
How many pills will you take today? Do you really need them? What good (and bad) will they do you?
For many of us prescription medications mean the difference between good and ill-health. There’s no denying their important place in fostering well-being for many. But is it time to reflect on the complex forces at work when managing disease and medications and how this impacts you the consumer?
Featuring leading UTS researchers in pharmacy and using example case studies, this public lecture takes a critical look at how medications are prescribed and consumed in Australia. It considers whether we are getting value for money, the ideal health outcomes we hope for and whether new approaches to the responsible use and explanation of medications could be adopted.
Speakers:
Professor Shalom (Charlie) Benrimoj
Charlie Benrimoj is head of the newly-created UTS School of Pharmacy. Formerly he was Foundation Professor of Pharmacy Practice then Dean of the Faculty of Pharmacy and then Pro-Vice Chancellor (Strategic Planning) at the University of Sydney. He is a visiting professor at the University of Granada with research interests in the future of community pharmacy. He is widely published - co-authoring Community Pharmacy: Strategic Change Management in 2007. He was Australian Pharmacist of the Year in 2000 and received the Andre Bedat award in 2010 from the International Pharmacy Federation.
Associate Professor Mary Bebawy
Mary Bebawy has spent more than 14 years in research and teaching positions in academia and two years in industry as a post doctoral preclinical drug development scientist with Johnson and Johnson, Research. She has consulted to academia and industry on assay development, drug discovery and cancer resistance mechanisms. At the UTS School of Pharmacy she specialises in the role and regulation of the xenobiotic cascade in drug disposition and in cancer multidrug resistance (MDR).
UTSPEAKS: is a free public lecture series presented by UTS experts discussing a range of important issues confronting contemporary Australia.
Use the hashtag #utspeaks to tweet about the lecture on Twitter.
OncoPrime - Patient derived platform for Biologics research Rachna Goyal
“OncoPrime™ platform uses patient-derived primary samples that offer clinically-relevant genotypic and
phenotypic diversity that translates better to the clinic vis-à-vis cell lines.
Functional assays, when adapted to OncoPrime™ can not only help in claiming physiological relevance
but also add additional layers of information for more informed clinical trials.
A Novel Eclectic Approach for Cancer Therapy with Liquid Knife & Immuno Thera...CrimsonpublishersCancer
Recent years cancer immunological therapy is getting very popular and many new drug have been approved by FDA like PD1 and PDl-1, however, in clinical practice of cancer treatment, it looks very limited efficacy for advanced cancer, so that physician started to use comprehensive plan by combination chemotherapy with PD1 as a novel strategy with a better clinical benefit. Since chemotherapy and radiation therapy always produce the side effect like loss hair, vomit and neutropenia, and surgery is limited for many later stages of cancers, also surgery damages body shapes with functions, esophageal cancer was removed with reconstruction and put stomach into chest and stomach never has normal function; a lot of cases showed surgery can’t be performed because tumor location in special site, like tumor location in posterior vaginal wall or vaginal carnal, surgery just is not allowed to do the procedure, if remove the tumor in these location, it will make a hole to connect to the rectal. Because of the extremely toxic side effects, many cancer patients cannot be successfully completed a surgery or a complete course of chemotherapy or radiation therapy, and some cases even die from the side effects of surgery or chemotherapy or radiation therapy due to a patient’s poor tolerance.
Non-animal models of NSCLC, Dr Dania MoviaKen Rogan
Dania Movia – PhD, MSc Senior Research Fellow Department of Clinical Medicine / Trinity Translational Medicine Institute Trinity College Dublin Predicting the efficacy of inhaled anti-cancer drugs in NSCLC patients
Cancer Moonshot, Data sharing and the Genomic Data CommonsWarren Kibbe
Gave the inaugural Informatics Grand Rounds at City of Hope on September 8th. NIH Commons, Genomic Data Commons, NCI Cloud Pilots, Cancer Moonshot and rationale for changing incentives around data sharing all discussed.
ZOOM: Pancreatic Cancer
• NEWS: Publication by Juan IOVANNA
• IMODI around the world: Meet the experts!
• FOCUS: From the bench to the bedside, INSERM U1068
• WEB-CATALOGUE: 20 in-vitro cell models available
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Cancer care is increasingly tailored to individual patients, who can undergo genetic or biomarker testing soon after diagnosis, to determine which treatments have the best chance of shrinking or eliminating tumours.
In this webinar, a pathologist and clinical oncologist discuss:
● how they are using these new tests,
● how they communicate results and treatment options to patients and caregivers, and
● how patients can be better informed on the kinds of tests that are in development or in use across Canada
View the video: https://youtu.be/_Wai_uMQKEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
Proteomics Modules designed to bring clinically relevant data, at any point, into the Drug Discovery Process. 1000s of proteins are plated from primary cells and are used to trap autoantibodies from diseased patients' blood sera. Results put a spotlight on highest probability targets.
“Europe Biosimilars Market & Pipeline Insight” Report Highlight:
Biosimilars Market Overview & Trend Analysis by Country
Biosimilars Introduction Timeline in Europe
Biosimilars Development & Market Authorization Guidelines
Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
Europe Biosimilars Pipeline: 93 Biosimilars
Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine)
Global cancer monoclonal antibodies marketKuicK Research
“Global Cancer Monoclonal Antibodies Market & Pipeline Insight” Report highlights:
Cancer Monoclonal Antibodies Market Overview
Emerging Market Dynamics: Favorable Parameters, Challenges & Growth Outlook
Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country
Cancer Monoclonal Antibodies in Pipeline: 605
Majority Cancer Monoclonal Antibodies Preclinical Phase: 258
Marketed Cancer Monoclonal Antibodies: 34
Cancer Monoclonal Antibodies Patent Analysis
Global cancer biosimilars market opportunity outlookKuicK Research
"Global Cancer Biosimilars Market Opportunity Outlook" Report Highlight & Findings:
Introduction & Mechanism of Cancer Biosimilars
Global Cancer Biosimilars Market Dynamics
FDA & EMA Guidelines on Development & Marketing of Biosimilars
Cancer Biosimilars Clinical Pipeline by Company, Indication & Phase
Cancer Biosimilars Clinical Pipeline: 100 Biosimilars
Marketed Cancer Biosimilars Clinical Insight
Marketed Cancer Biosimilars: 15 Biosimilars
“India Baby Care Market Outlook 2018” report Highlights:
Baby Care Market Overview
Market by Product Segment
Consumer Purchasing & Spending Behavior
Point of Purchase for Multiple Products
Favorable Market Dynamics
Future Growth Strategies
Preferred Operating Business Model
Key Companies Business Overview & Product Portfolio
Functionality Based Fixing of Weight for Non-functional parameters of a web s...Editor IJCATR
In recent years, web services open the way to global business development through B2B integration and they used with
different business applications to accommodate their services. So while selecting a service, the first preference is given to the
functional properties of the web service and then a best web service is selected from the list by considering the expected quality. The
QoS of a web service is also depends on the variant nonfunctional parameters of its service which may subject to changes because of
network and other related factors. While considering the performance of a service, the overall quality is always preferred but the actual
functionality of the service is based on the weight fixed for the non functional parameters like response time, throughput, etc... So
assigning functionality based weight for the non functional parameters are used to achieve the assured quality of the service. In this
paper we are proposing the system that gives importance for the non functional parameters such as response time, throughput,
availability, success ability, reliability for which the weight is set based on functionality and requirement of aparticular business
application.
A New Approach to Segmentation of On-Line Persian Cursive WordsEditor IJCATR
Segmentation approaches, as processes that divide word into smaller parts which contain one letter at most, have important
effect on cursive word recognition. While online cursive word recognition became applied technology in Latin and Chinese languages,
complex structural features in Arabic-based script made it an important field of study in Persian and Arabic languages. In this paper,
by introducing of Standard Persian Handwriting, we proposed a novel approach to segmentation online Persian cursive script based on
width of letter's body in Persian language. Results are shown 99.86% accuracy in detection of expected segmentation points, while
recognized extra points reduced 93.73% compared to our previous methods.
User participation in ERP Implementation: A Case-based StudyEditor IJCATR
Information Systems (IS), such as Enterprise Resource Planning (ERP) systems, are being developed and used in
organizations to achieve their business goals and to enhance organizational effectiveness. The effect of user participation on
successful systems development and implementation of ERP systems continues to be an area of interest to researchers. Common
understanding has been that extensive user participation is not only important, but absolutely essential to system success. Even with
this understanding of user participation as one of the critical factor in successful IS development and implementation, empirical studies
have been unable to conclusively link user participation to systems success. This paper uses a private university as a case study to
examine the role played by user participation in the implementation of an ERP system. In order to achieve its objective, this study
adopted a mixed method where both qualitative and quantitative approaches were used in the collection of data. The results of the
study reveal that user participation has a positive impact on the likelihood of ERP system success, user participation by choice is the
best, user participation leads to better understanding of system requirements, the more participation the more the satisfied the users are,
and participation builds support for the system during implementation. From our results we conclude that user participation in ERP
system implementation is critical for successful implementation.
Finger Vein Detection using Gabor Filter, Segmentation and Matched FilterEditor IJCATR
This paper propose a method of personal identification based on finger-vein patterns. An image of a finger captured by the web camera under the IR light transmission contains not only the vein pattern itself; but also shade produced by various thickness of the finger muscles; bones; and tissue networks surrounding the vein. In this paper; we intro-duce preliminary process to enhance the image quality worsened by light effect and noise produced by the web camera; then segment the vein pattern by using adaptive threshold method and matched them using improved template matching. The main purposes of this paper are to investigate finger-vein technology; the applicable fields and whether finger-vein detection can solve the problems fingerprint detection imposes in certain industries
Cancer nanomedicine market & pipeline insight 2015KuicK Research
“Cancer Nanomedicine Market & Pipeline Insight 2015” Report Highlight
Nanomedicine for Cancer Therapies
Cancer Nanoparticles Drug Delivery Systems Classification
Mechanism of Cancer Nanomedicine Therapy
Cancer Nanomedicine Clinical Pipeline Overview
Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Cancer Nanomedicine Clinical Pipeline: 79 Drugs
Marketed Cancer Nanomedicine: 8 Drugs
Download Global cancer nanomedicine market outlook 2022KuicK Research
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview and Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design and Strategy
Cancer Nanomedicine as Diagnostic and Therapeutics Tool
Global Cancer Nanomedicine Market Overview and Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Download Nanoparticle drug delivery market & clinical pipeline insightKuicK Research
“Nanoparticle Drug Delivery Market & Clinical Pipeline Insight” Report Highlights:
Nanoparticle Drug Delivery Market Overview
Nanoparticle Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 190
Majority of Nanoparticle Drug in Preclinical Phase: 70
Marketed Nanoparticle Drugs: 12
Suspended & Discontinued Drug Profiles
Nanoparticle drug delivery market & clinical pipeline insightRajesh Sarma
Nanoparticle Drug Delivery Market & Clinical Pipeline Insight” Report Highlights:
Nanoparticle Drug Delivery Market Overview
Nanoparticle Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 190
Majority of Nanoparticle Drug in Preclinical Phase: 70
Marketed Nanoparticle Drugs: 12
Suspended & Discontinued Drug Profiles
Global cancer nanomedicine market outlook 2022Rajesh Sarma
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview & Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design & Strategy
Cancer Nanomedicine as Diagnostic & Therapeutics Tool
Global Cancer Nanomedicine Market Overview & Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
A General Overview of Nano Medicine-Efficacy in Therapeutic Science and Curre...Berklin
Nanotechnology’s introduction has dramatically improved a number of scientific fields, one of which is medicinal research. Nanomedicine is aimed to offer healthcare medications and chemicals a new dimension. The small size of nanoparticles, permits them to circulate in the body without interrupting oxygenation and escape filtration by both the renal and gastrointestinal networks. These are the few properties that distinguish them apart from traditional therapeutic procedures. The increased permeability and durability effect result in successful penetration inside the tumor tissues, providing cancer treatment a new lease on life. Efficient transportation pathways, on the other hand, produce genotoxicity and mutagenicity by interacting with genes that are essential for smooth functioning. As the specific interactions of nanomedicines with biological systems are still unknown, comprehending nanomedicines' toxicological effects is tough. The lack of regulatory direction in this field remains a research gap that we would want to examine in this study.
A General Overview of Nano Medicine-Efficacy in Therapeutic Science and Curre...ceijjournals
Nanotechnology’s introduction has dramatically improved a number of scientific fields, one of which is
medicinal research. Nanomedicine is aimed to offer healthcare medications and chemicals a new
dimension. The small size of nanoparticles, permits them to circulate in the body without interrupting
oxygenation and escape filtration by both the renal and gastrointestinal networks. These are the few
properties that distinguish them apart from traditional therapeutic procedures. The increased permeability
and durability effect result in successful penetration inside the tumor tissues, providing cancer treatment a
new lease on life. Efficient transportation pathways, on the other hand, produce genotoxicity and
mutagenicity by interacting with genes that are essential for smooth functioning. As the specific
interactions of nanomedicines with biological systems are still unknown, comprehending nanomedicines'
toxicological effects is tough. The lack of regulatory direction in this field remains a research gap that we
would want to examine in this study.
Cancer targeted therapy market & clinical insight 2015KuicK Research
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
Introduction & Categorization of Cancer Targeted Therapies
Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
Global Cancer Targeted Therapeutics Market Dynamics
Future Prospects of Cancer Targeted Therapies
Global cancer stem cell therapy market outlook 2020KuicK Research
“Global Cancer Stem Cell Therapy Market Outlook 2020” Report Highlight:
Introduction & Classification of Stem Cells
Stem Cell Transplants Classification
Cancer Stem Cell Therapy Mechanism of Action
Global Cancer Stem Cell Market Analysis
Global Cancer Stem Cell Clinical Pipeline by Company & Phase
Global Cancer Stem Cell Clinical Pipeline: 32 Therapies
Global Cancer Stem Cell Market Dynamics: Challenges & Favorable Parameters
Global Cancer Stem Cell Market Future Outlook
Nanoparticle Drug Delivery Systems for Cancer TreatmentAranca
The engineered nanoparticles are effectively used for cancer treatment due to their targeted drug delivery approach. Download the Aranca report on Technology and Patent Research for current research trends and developments.
The engineered nanoparticles are effectively used for cancer treatment due to their targeted drug delivery approach. Download the Aranca report on Technology and Patent Research for current research trends and developments.
“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:
Cancer Immunotherapy Market Overview
Cancer Immunotherapy Market Dynamics
Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
Cancer Vaccine Clinical Pipeline by Phase & Country
Oncolytic Viruses Clinical Pipeline by Phase & Country
Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
Cancer Cell Therapy Clinical Trial Insight by Phase & Country
Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40 Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical Pipeline.
We have 13 research and development projects within:
• Research
• Oncology
• Respiratory, Inflammation and Autoimmunity
• Cardiovascular and Metabolic Disease
• Antibody Discovery and Protein Engineering
• Pathology
• Biopharmaceutical Development
• Cell Culture and Fermentation Sciences
• Formulation Sciences
• Analytical Biotechnology Science
Cancer immunotherapy market & clinical pipelineKuicK Research
“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:
Cancer Immunotherapy Market Overview
Cancer Immunotherapy Market Dynamics
Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
Cancer Vaccine Clinical Pipeline by Phase & Country
Oncolytic Viruses Clinical Pipeline by Phase & Country
Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
Cancer Cell Therapy Clinical Trial Insight by Phase & Country
Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40
Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical
Pipeline
These slides use concepts from my (Jeff Funk) course entitled analyzing hi-tech opportunities to show how nanotechnology for drug deliver is becoming economically feasible.
Download Global cancer monoclonal antibodies market & pipeline insightKuicK Research
“Global Cancer Monoclonal Antibodies Market & Pipeline Insight” Report highlights:
Cancer Monoclonal Antibodies Market Overview
Emerging Market Dynamics: Favorable Parameters, Challenges & Growth Outlook
Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country
Cancer Monoclonal Antibodies in Pipeline: 605
Majority Cancer Monoclonal Antibodies Preclinical Phase: 258
Marketed Cancer Monoclonal Antibodies: 34
Cancer Monoclonal Antibodies Patent Analysis
Global cancer monoclonal antibodies market & pipeline insightKuicK Research
“Global Cancer Monoclonal Antibodies Market & Pipeline Insight” Report highlights:
Cancer Monoclonal Antibodies Market Overview
Emerging Market Dynamics: Favorable Parameters, Challenges & Growth Outlook
Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country
Cancer Monoclonal Antibodies in Pipeline: 605
Majority Cancer Monoclonal Antibodies Preclinical Phase: 258
Marketed Cancer Monoclonal Antibodies: 34
Cancer Monoclonal Antibodies Patent Analysis
Similar to Cancer nanomedicine market & pipeline insight 2015 (20)
Global cancer cdk inhibitors market & clinical pipeline outlook 2022KuicK Research
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report highlights:
* Selectivity and Working Mechanism of a Cancer CDKs Inhibitor
* Recent Advances in the CDKs Related Cancer Therapy
* Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline
* Market Opportunity Assessment: More Than US$ 20 Billion (2022)
* Price Analysis of Cancer CDKs Inhibitors:
* Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)
Cd antigen cancer therapy market outlook & clinical trials insight 2023KuicK Research
“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights:
• Market Opportunity Assessment: More than US$ 60 Billion by 2023
• Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs
• Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline
• Dosage & Price Analysis on Key Drugs
• Mechanism of CD Antigen Cancer Therapeutics
• Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
• Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
Global orphan drug market designation status clinical pipeline trials insigh...KuicK Research
“Global Orphan Drug Market & Clinical Pipeline Insight 2023” Report Highlights:
• Clinical Insight on 800 Orphan Drugs
• Patent Insight, Orphan Designated Indication & Region/Country
• Marketed Orphan Drugs: More Than 300
• Maximum Orphan Designated Drugs in Phase-II: More Than 200
• Global Orphan Drug Designation Criteria
• FDA & EMA Guidelines
“US Shale Gas Industry Analysis” Report Highlight:
* US Shale Gas Industry Overview
* Shale Gas Exploration, Technical and Technology Aspects
* US Shale Gas Reserve Analysis: Technical & Recoverable Reserves
* Investments in Shale Gas Exploration & Production
* US Shale Gas Sector Dynamics
* Shale Boom to Drive LNG Export Projects
Download Us biosimilars market opportunity & clinical pipeline analysisKuicK Research
“US Biosimilars Market Opportunity & Clinical Pipeline Analysis” Report Highlight:
* US Biosimilars Market Introduction
* US Biosimilars Regulatory Scenario
* Unique Features of US Biosimilars Market
* Impact of Biosimilars in US Market
* Impact of Reimbursement Policies on US Biosimilars Market
* Zarxio: First Approved Biosimilar in US
* US Biosimilar Clinical Pipeline By Company, Indication & Phase
* US Biosimilar Clinical Pipeline: 104 Biosimilars
* Marketed Biosimilars: 1 Biosimilar*
Download Uae nuclear power sector opportunity analysisKuicK Research
“UAE Nuclear Power Sector Opportunity Analysis” Report Highlight:
* UAE Energy Policy beyond Oil & Gas
* UAE Nuclear Power Sector Overview
* UAE Nuclear Power Sector Dynamics
* Nuclear Power Sector Management & Regulatory Framework
* Nuclear Power Sector Regulations
* Details of Nuclear Power Plants in UAE
* UAE Nuclear Power Sector Future Outlook
Download Turkey wind power sector outlook 2017KuicK Research
“Turkey Wind Power Sector Outlook 2017” gives comprehensive insight on following aspect related to wind power sector development in Turkey:
* Wind Power Sector Overview
* Wind installed Capacity & Generation
* Operating Wind Farms by Province & Company
* Onshore & Offshore Wind Potential
* Emerging Trends
* Policy Framework
* Competitive Landscape
Download South korea wind power sector analysis 2013KuicK Research
“South Korea Wind Power Sector Analysis 2013” research report discusses following aspect related to emerging wind power sector in South Korea:
* Current Sector Trends
* Onshore & Offshore Wind Potential
* Wind Power Sector Indicators
* Operating Wind Farms
* Future Outlook & Sector Emerging Trends
* Regulatory & Policy Framework
* Competitive Landscape
Download Saudi arabia airport privatization opportunity outlook 2022KuicK Research
“Saudi Arabia Airport Privatization Opportunity Outlook 2022” report highlights:
Saudi Arabia Aviation Industry Overview
Privatization in Saudi Arabia
Investment and Expansion Opportunities for International Investors
Civil Aviation Laws and Policies Framework
Ongoing Privatization Projects
Privatization Build - Operateandndash;Transfer (BOT) Business Model
Download Non hodgkin lymphoma therapeutics market & pipeline insightKuicK Research
“Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight:
Global Non Hodgkin Lymphoma Market Overview
Mechanism of Non Hodgkin Lymphoma Therapeutics
Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company
Global Non Hodgkin Lymphoma Pipeline: 204 Drugs
Majority of the Drugs are in Phase-I: 54 Drugs
Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs
Patent Analysis by Country, Year & Compositions
Download Japan generics drug market outlook 2020KuicK Research
“Japan Generics Drug Market Outlook 2020” Report Highlights:
Introduction to Japanese Generic Drug Market
Attractiveness of Japanese Generic Market
Super Generics in Japan
Japan Healthcare System & Generic Drugs
Different Parameters for Generic & Branded Drugs
Comparison of Generic Drugs in US & Japan
Japan Generics Drug Market Analysis
Japan Generics Drug Market Future Prospects
Download India urban and industrial waste to energy marketKuicK Research
The Urban and Industrial waste based power projects have been witnessing upward trend in recent years driven by increasing investments from private sector and ongoing government initiatives to promote generation of power from urban and industrial waste. The overall installed capacity of grid connected waste power projects surpassed 70 MW by end of 2011 as compare to more than 90 MW of off grid waste base power projects.
Considering the huge potential to convert waste to energy in India, the Ministry of Environment and Forests had formulated the Municipal Solid Wastes Management and Handling Rules in 2000. Waste to Energy is understood as a renewable technology, and comes under the overall guidance and facilitation of the Ministry of Non Renewable Energy of India, which has announce finacila incentives and assistance programme in.
Download India nuclear power sector generation and investment opportunity out...KuicK Research
“India Nuclear Power Sector Generation and Investment Opportunity Outlook 2032” report highlights:
India Nuclear Power Sector Overview
India Nuclear Power Sector Indicators
India Existing and upcoming Nuclear Power Plants Overview
Indian Nuclear Power Regulatory and Policy Framework
India Nuclear Power Plants Infrastructure
India Nuclear Fuel Supply Scenario
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Cancer nanomedicine market & pipeline insight 2015
1. Cancer Nanomedicine Market & Pipeline Insight 2015
During the last decade, there has been significant impact of the emergence of
nanotechnology on clinical therapeutics. The pharmaceutical industry has witnessed
advances in biocompatible nanoscale drug carriers in the form of liposomes and polymeric
nanparticles which have the potential to deliver numerous drugs with more efficiency and
safety. The advantages of nanoparticle drug delivery, specifically, at the systemic level,
include longer circulation half-lives, improved pharmacokinetics and reduced side effects
which are major reasons for its increasing popularity. In the field of cancer therapy, the
nanoparticles could possibly depend heavily on the enhanced permeability and retention
effect which is caused by leaky tumor vasculatures for better drug accumulation at the
tumor sites. Owing to such benefits, the therapeutic nanoparticles as a form of drug
delivery has become a very promising field and has the potential to successfully replace
traditional chemotherapy.
Scientists and engineers have been specifically researching on discovering different
approaches to deliver multiple therapeutic agents using a single drug nanocarrier. Given
the fact that application of multiple drugs could possibly suppress the notorious
phenomenon of cancer chemo-resistance, these efforts have been motivated to a great
extent. It has been observed that the cancer cells tend to exhibit a diminishing response
over the course of a chemo-treatment because they acquire defense mechanisms by over
expressing drug efflux pumps, increasing drug metabolism, enhancing self-repairing ability
or expressing altered drug targets. In order to reduce the cancer drug resistance for better
therapeutic effectiveness, the "combination chemotherapy" has been adopted for a long
time in the clinics as a primary cancer treatment regimen.
While on the one hand, applying multiple drugs with different molecular targets could
possibly raise the genetic barriers needed to be overcome for cancer cell mutations,
thereby delaying the cancer adaptation process. On the other hand, it has been proved
that multiple drugs targeting the same cellular pathways could sometimes function
synergistically for higher therapeutic efficacy and higher target selectivity. However,
there are many shortcomings in the current combination chemotherapies. These include
varying pharmacokinetics, biodistrubtions and membrane transport properties among
different drug molecules which tend to make dosing and scheduling optimization
extremely difficult. These challenges have made the researchers and clinicians to
investigate more efficient approaches to incorporating nanotechnology with combination
chemotherapy.
2. The future years are expected to be bright with regards to the development of
nanoparticle drug delivery systems for cancer treatment. The identification of
nanoparticle materials which are relatively safe and effective in delivering therapeutic
agents to the target tumor sites is the need of the hour. The protein polymers from
natural sources are considered to be promising materials for constructing the nanocarrier
systems. With the commercial success of albumin-based nanoparticles, there has been
significant amount of interest in other proteins also. By rationally designing protein
nanoparticles based on their behaviors in the tumor microenvironment and based on
cancer cell biology, improved efficacy and safety of cancer therapy can be achieved.
"Cancer Nanomedicine Market & Pipeline Insight 2015" Report Highlight
Nanomedicine for Cancer Therapies
Cancer Nanoparticles Drug Delivery Systems Classification
Mechanism of Cancer Nanomedicine Therapy
Cancer Nanomedicine Clinical Pipeline Overview
Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
Cancer Nanomedicine Clinical Pipeline: 79 Drugs
Marketed Cancer Nanomedicine: 8 Drugs
For Report Sample Contact: neeraj@kuickresearch.com
3. Table of Contents
1. Introduction to Nanomedicine
2. Nanomedicine for Cancer Therapies
3. Need for Nanomedicine in Cancer Therapy
4. Cancer Nanoparticles Drug Delivery Systems Classification
5. Mechanism of Cancer Nanomedicine Therapy
6. Global Cancer Nanomedicine Market Outlook
6.1 Current Market Scenario
6.2 Cancer Nanomedicine Clinical Pipeline Overview
7. Global Cancer Nanomedicine Market Dynamics
7.1 Favorable Market Parameters
7.2 Commercialization Challenges
8. Global Cancer Nanomedicine Market Future Prospects
9. Cancer Nanomedicine Clinical Pipeline by Company, Indication &
Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
10. Marketed Cancer Nanomedicine by Company & Indication
4. 11. Suspended & No Development Reported in Cancer Nanomedicine
Clinical Pipeline
11.1 No Development Reported
11.2 Discontinued
12. Competitive Landscape
12.1 Abraxis BioScience
12.2 Access Pharmaceuticals
12.3 Alnylam Pharmaceuticals
12.4 Arrowhead Research
12.5 BIND Biosciences
12.6 Epeius Biotechnologies
12.7 Nanobiotix
12.8 NanoCarrier
12.9 Nippon Kayaku
12.10 Samyang
12.11 Takeda Pharmaceutical
List of Figures
Figure 1-1: Introduction to Nanomedicine
Figure 1-2: Applications Areas of Nanomedicine
Figure 2-1: Technology Evolution of Targeted Drug Delivery using Nanoparticles
for Cancer Treatment
Figure 3-1: Need & Importance of Nano Drug Delivery for Cancer
Figure 4-1: Types of Nanoparticles Drug Delivery Systems
Figure 5-1: Mechanism of Cancer Nanomedicine Therapy
Figure 5-2: Multiblock Polymer Nanoparticles Attacks Tumors- Step by Step
Process of Drug Delivery
Figure 6-1: Novel Drug Delivery Systems for Cancer
5. Figure 6-2: Cancer Nanomedicine Pipeline by Phase (%), 2015
Figure 6-3: Cancer Nanomedicine Pipeline by Phase (Number), 2015
Figure 6-4: No Development Reported in Cancer Nanomedicine Pipeline by Phase
(%), 2015
Figure 6-5: No Development Reported in Cancer Nanomedicine Pipeline by Phase
(Number), 2015
Figure 6-6: Discontinued Cancer Nanomedicine Pipeline by Phase (%), 2015
Figure 6-7: Discontinued Cancer Nanomedicine Clinical Pipeline by Phase
(Number), 2015
Figure 12-1: Arrowhead Research Corporation Clinical Pipeline
Figure 12-2: NanoCarrier Clinical Pipeline
For Report Sample Contact: neeraj@kuickresearch.com